Skip to main content

Allergic Rhinitis

72
Pipeline Programs
30
Companies
50
Clinical Trials
1 recruiting
14
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
12
2
17
1
13
27
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
150%
Small Molecule
150%
+ 103 programs with unclassified modality

On Market (14)

Approved therapies currently available

GSK
FLOVENT HFAApproved
fluticasone propionate
GSK
inhalation2004
395M Part D
ALVESCOApproved
ciclesonide
Unknown Company
inhalation2008
35M Part D
OMNARISApproved
ciclesonide
Unknown Company
nasal2006
923K Part D
ZETONNAApproved
ciclesonide
Unknown Company
nasal2012
323K Part D
Bayer
CLARITINApproved
loratadine
Bayer
oral1996
GSK
FLOVENT DISKUS 50Approved
fluticasone propionate
GSK
inhalation2000
GSK
FLONASE ALLERGY RELIEFApproved
fluticasone propionate
GSK
nasal2014
GSK
FLONASEApproved
fluticasone propionate
GSK
nasal1994
Bayer
CLARITIN HIVES RELIEF REDITABApproved
loratadine
Bayer
oral1996
Bayer
CLARITIN REDITABSApproved
loratadine
Bayer
oral1996
GSK
FLOVENT DISKUS 250Approved
fluticasone propionate
GSK
inhalation2000
Bayer
CHILDREN'S CLARITINApproved
loratadine
Bayer
oral2006
Bayer
CLARITIN HIVES RELIEFApproved
loratadine
Bayer
oral1996
GSK
FLOVENT DISKUS 100Approved
fluticasone propionate
GSK
inhalation2000

Competitive Landscape

47 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
8 programs
1
2
1
3
Fluticasone furoatePhase 4
INCSPhase 4
fluticasone furoatePhase 4
Fluticasone propionatePhase 3
GSK1004723Phase 2
+3 more programs
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
6 programs
3
2
PURETHAL Birch, 20.000 AUM/mlPhase 41 trial
PURETHAL Grasses, 20.000 AUM/mlPhase 41 trial
PURETHAL Mites 20,000 AUeq/mlPhase 21 trial
SUBLIVAC FIX BirchPhase 21 trial
SUBLIVAC FIX Phleum Prat.Phase 21 trial
+1 more programs
Active Trials
NCT03414801Completed6Est. Jul 2018
NCT00973453Completed48Est. Aug 2010
NCT01639768Completed270Est. Apr 2013
+3 more trials
GSK
GSKLONDON, United Kingdom
3 programs
1
Cetrizine hydrochlorideN/A1 trial
Fluticasone PropionatePHASE_11 trial
GSK256066PHASE_21 trial
Active Trials
NCT02020902Completed1,552Est. Jan 2016
NCT00348361Completed48
NCT00612118Completed70Est. May 2008
Pfizer
PfizerNEW YORK, NY
3 programs
1
1
1
CetirizinePhase 4
PF-03654764Phase 21 trial
IbuprofenPhase 1Small Molecule1 trial
Active Trials
NCT01064726Completed18Est. Apr 2010
NCT01033396Completed64Est. May 2010
Alcon
AlconFORT WORTH, TX
2 programs
1
1
Olopatadine 0.6% / Azelastine 137 mcgPhase 41 trial
Olopatadine Hydrochloride Nasal Spray 0.6%Phase 21 trial
Active Trials
NCT00794144Completed132
NCT00772304Completed102
Bayer
BayerLEVERKUSEN, Germany
2 programs
1
1
LoratadinePhase 41 trial
Azelastine hydrochloridePhase 31 trial
Active Trials
NCT04264637Completed110Est. Mar 2021
NCT04162795Completed468Est. Nov 2019
UNION therapeutics
2
Fluticasone Nasal 50 Mcg/Inh Nasal Spray, Azelastine Nasal 140 Mcg/Inh Nasal SprayPhase 41 trial
Intranasal corticosteroidsPhase 41 trial
Active Trials
NCT05080322Unknown150Est. Jan 2025
NCT07294326Not Yet Recruiting50Est. Nov 2026
Menarini
MenariniGermany - Dresden
1 program
1
BilastinePhase 41 trial
Active Trials
NCT02576041Completed19Est. Dec 2015
Handok
HandokKorea - Seoul
1 program
1
CiclesonidePhase 41 trial
Active Trials
NCT01430260Completed349Est. Jul 2012
Ergomed
1 program
1
PURETHAL Birch, 20.000 AUM/mlPhase 4
EMS
7 programs
7
DEP114Phase 31 trial
Desloratadine + PrednisolonePhase 31 trial
Dexchlorpheniramine + BetamethasonePhase 31 trial
EMS Mometasone gelPhase 31 trial
EMS Mometasone gelPhase 31 trial
+2 more programs
Active Trials
NCT06272409Not Yet Recruiting318Est. Apr 2027
NCT01720485Unknown234Est. Mar 2014
NCT01529229Completed210Est. Oct 2014
+4 more trials
Keymed Biosciences
2
1
CM310Phase 31 trial
CM310Phase 21 trial
Stapokibart InjectionPhase 21 trial
Active Trials
NCT05908721Completed100Est. Dec 2023
NCT06525597Recruiting120Est. Oct 2025
NCT05908032Completed108Est. Dec 2023
Abdi Ibrahim
1 program
1
AI201901Phase 31 trial
Active Trials
NCT04729517Completed210Est. May 2023
Biocorp
1 program
1
AIT dropsPhase 31 trial
Active Trials
NCT03990272Completed702Est. Oct 2017
Syneos Health
Syneos HealthNC - Morrisville
1 program
1
HDM SLIT-tabletPhase 31 trial
Active Trials
NCT04541004Completed253Est. Apr 2021
Inmunotek
1 program
1
3,000 MM09Phase 2/31 trial
Active Trials
NCT05641272Not Yet Recruiting90Est. Dec 2026
Sandoz
SandozAustria - Kundl
6 programs
1
3
QAV680 + Cetirizine PlaceboPhase 21 trial
QAW039Phase 21 trial
QAX576Phase 21 trial
NVP-VAK694Phase 11 trial
Dust mite extract, Fluticasone, MethacholineN/A1 trial
+1 more programs
Active Trials
NCT00513487Completed18Est. Nov 2007
NCT04648930Completed50Est. Nov 2022
NCT00620230Completed46Est. Apr 2008
+3 more trials
MSD
MSDIreland - Ballydine
4 programs
1
1
epinastine 0.1%Phase 2
MK-8237Phase 1
Diesel Exhaust Particles and Leukotriene ProductionN/A
Swab of vestibule and middle meatus of noseN/A
Sharp Therapeutics
1
1
epinastine 0.1%Phase 21 trial
MK-8237Phase 11 trial
Diesel Exhaust Particles and Leukotriene ProductionN/A1 trial
Swab of vestibule and middle meatus of noseN/A1 trial
Active Trials
NCT00915447Withdrawn0Est. Apr 2013
NCT01461200Completed40Est. Feb 2012
NCT01852825Completed26Est. Aug 2015
+1 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
1
2
AZD8848Phase 21 trial
BudesonidePhase 21 trial
AZD8848Phase 11 trial
Active Trials
NCT00770003Completed103Est. Feb 2010
NCT01185080Completed93Est. Jan 2012
NCT00641693Completed650Est. May 2005
Emergo Therapeutics
1
NorketotifenPhase 21 trial
Active Trials
NCT03887026Completed36Est. May 2019
Martin Pharmaceuticals
1
saline with 1mg/ml Histamine basePhase 1/2
Bryan Corporation
1
saline with 1mg/ml Histamine basePhase 1/21 trial
Active Trials
NCT01989897Withdrawn0Est. Nov 2015
Kite Pharma
Kite PharmaCA - El Segundo
2 programs
2
CAL-101Phase 11 trial
CAL-263Phase 11 trial
Active Trials
NCT00836914Completed41Est. Mar 2009
NCT01066611Completed48Est. Apr 2010
Immunomic Therapeutics
1
CryJ2-DNA-LAMP plasmid vaccine by intradermal injectionPhase 1Vaccine1 trial
Active Trials
NCT02146781Completed22Est. Mar 2015
Amber Therapeutics
1 program
1
Grass pollen extractPhase 11 trial
Active Trials
NCT01982474Unknown18Est. Dec 2016
Lundbeck
LundbeckDenmark - Copenhagen
1 program
1
Lu AG09222Phase 11 trial
Active Trials
NCT05126316Completed30Est. Aug 2022
Hanlim Pharm
1 program
1
Test-Bepotastine salicylate 9.64 mgPhase 11 trial
Active Trials
NCT01897428Completed26Est. Aug 2011
Hal Allergy
Hal AllergyNetherlands - Leiden
6 programs
PURETHAL Mites 20,000 AUeq/mlPHASE_2
SUBLIVAC FIX BirchPHASE_2
SUBLIVAC FIX Phleum Prat.PHASE_2
SUBLIVAC FIX phleum prat.PHASE_2
PURETHAL Birch, 20.000 AUM/mlPHASE_4
+1 more programs
UCB Pharma
UCB PharmaBelgium - Brussels
4 programs
Levocetirizine oral solutionPHASE_21 trial
LevocetirizinePHASE_31 trial
Levocetirizine 1.25 mgPHASE_31 trial
LevocetirizinePHASE_41 trial
Active Trials
NCT00152412Completed30Est. Dec 2004
NCT00619801Completed173Est. Jul 2008
NCT00628108Completed69Est. Sep 2008
+1 more trials

+17 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
UNION therapeuticsIntranasal corticosteroids
UNION therapeuticsFluticasone Nasal 50 Mcg/Inh Nasal Spray, Azelastine Nasal 140 Mcg/Inh Nasal Spray
BayerLoratadine
City TherapeuticsCetirizine Hydrochloride 1 MG/ML
MenariniBilastine
Allergy TherapeuticsPURETHAL Birch, 20.000 AUM/ml
HandokCiclesonide
Allergy TherapeuticsPURETHAL Grasses, 20.000 AUM/ml
AlconOlopatadine 0.6% / Azelastine 137 mcg
UCB PharmaLevocetirizine
SanofiFexofenadine
EMSDEP114
EMSMAZ-101association
Keymed BiosciencesCM310
EMSMAGNÓLIA NASAL GEL

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 8,417 patients across 50 trials

NCT07294326UNION therapeuticsIntranasal corticosteroids

A Prospective, Randomized, Controlled Study Comparing the Efficacy of Intranasal Corticosteroids (INCS) Combined With Intranasal Antihistamines (INAH) and INCS Combined With Oral Antihistamines (OAH) in the Treatment of Moderate to Severe Allergic Rhinitis Symptoms

Start: Jan 2026Est. completion: Nov 202650 patients
Phase 4Not Yet Recruiting
NCT05080322UNION therapeuticsFluticasone Nasal 50 Mcg/Inh Nasal Spray, Azelastine Nasal 140 Mcg/Inh Nasal Spray

Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis

Start: Sep 2021Est. completion: Jan 2025150 patients
Phase 4Unknown

A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies

Start: Nov 2019Est. completion: Nov 2019468 patients
Phase 4Completed
NCT03340740City TherapeuticsCetirizine Hydrochloride 1 MG/ML

The Effect of Cetirizine on Bronchoconstriction

Start: May 2018Est. completion: Aug 2021
Phase 4Completed

Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria

Start: Oct 2015Est. completion: Dec 201519 patients
Phase 4Completed
NCT01918956Allergy TherapeuticsPURETHAL Birch, 20.000 AUM/ml

PURETHAL Birch RUSH Study

Start: Sep 2013Est. completion: Apr 2014120 patients
Phase 4Completed

Omnaris Versus Levocetirizine Phase 4 Study

Start: Jan 2011Est. completion: Jul 2012349 patients
Phase 4Completed
NCT01059266Allergy TherapeuticsPURETHAL Grasses, 20.000 AUM/ml

PURETHAL Grasses Rush Study

Start: Feb 2010Est. completion: Sep 2010150 patients
Phase 4Completed
NCT00772304AlconOlopatadine 0.6% / Azelastine 137 mcg

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

Start: Oct 2008102 patients
Phase 4Completed
NCT00355771UCB PharmaLevocetirizine

Levocetirizine 5 mg: Reduction of Symptoms, Airway Resistance and Sleep Impairment in Persistent Allergic Rhinitis

Start: Jun 2006Est. completion: Nov 2007100 patients
Phase 4Completed
NCT00636870SanofiFexofenadine

Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine

Start: Feb 2003Est. completion: Jan 2004220 patients
Phase 4Completed

Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.

Start: Feb 2025Est. completion: Apr 2027318 patients
Phase 3Not Yet Recruiting
NCT05684380EMSMAZ-101association

Efficacy and Safety of MAZ-101 in the Treatment of Persistent Allergic Rhinitis (PER)

Start: Sep 2024Est. completion: May 2025514 patients
Phase 3Unknown

Study of CM310 in Subjects With Allergic Rhinitis

Start: Aug 2023Est. completion: Dec 2023108 patients
Phase 3Completed
NCT04670653EMSMAGNÓLIA NASAL GEL

Efficacy and Safety of Magnólia Nasal Gel in the Treatment of Allergic Rhinitis

Start: Aug 2022Est. completion: Oct 20230
Phase 3Withdrawn

Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients

Start: Apr 2021Est. completion: May 2023210 patients
Phase 3Completed

Adolescent Mite Allergy Safety Evaluation

Start: Sep 2020Est. completion: Apr 2021253 patients
Phase 3Completed
NCT04264637BayerAzelastine hydrochloride

Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis

Start: Feb 2020Est. completion: Mar 2021110 patients
Phase 3Completed
NCT02953366EMSEMS Mometasone gel

Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis

Start: May 2019Est. completion: May 20200
Phase 3Withdrawn
NCT02953379EMSEMS Mometasone gel

Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis

Start: May 2019Est. completion: Mar 20200
Phase 3Withdrawn

Demonstration of Equivalence and Early Onset of a Novel Anti-allergic Nasal Spray Compared to Marketed Nasal Spray

Start: Nov 2018Est. completion: Apr 201982 patients
Phase 3Completed

Safety and Efficacy of Sublingual Immunotherapy for Allergic Rhinitis Due to Artemisia Annua

Start: Mar 2017Est. completion: Oct 2017702 patients
Phase 3Completed
NCT01529229EMSDexchlorpheniramine + Betamethasone

Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment

Start: Nov 2013Est. completion: Oct 2014210 patients
Phase 3Completed
NCT01720485EMSDesloratadine + Prednisolone

Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment

Start: Oct 2013Est. completion: Mar 2014234 patients
Phase 3Unknown

Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Start: Jan 2013Est. completion: Oct 2013547 patients
Phase 3Completed

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

Start: Oct 2012Est. completion: Feb 201399 patients
Phase 3Completed
NCT00628108UCB PharmaLevocetirizine 1.25 mg

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

Start: Mar 2008Est. completion: Sep 200869 patients
Phase 3Completed
NCT00619801UCB PharmaLevocetirizine

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 1 to Less Than 6 Years Suffering From Allergic Rhinitis or Chronic Urticaria of Unknown Origin

Start: Mar 2008Est. completion: Jul 2008173 patients
Phase 3Completed

Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract

Start: Nov 2023Est. completion: Dec 202690 patients
Phase 2/3Not Yet Recruiting
NCT00674700Stallergenes Greer300 IR house dust mites allergen extract tablet

Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis

Start: Oct 2007Est. completion: Feb 2010509 patients
Phase 2/3Completed
NCT06525597Keymed BiosciencesStapokibart Injection

Study of Stapokibart Injection in Patients With Allergic Rhinitis

Start: Sep 2024Est. completion: Oct 2025120 patients
Phase 2Recruiting

Study of CM310 in Patients With Allergic Rhinitis

Start: Aug 2023Est. completion: Dec 2023100 patients
Phase 2Completed

Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Start: Aug 2022Est. completion: Jul 2023217 patients
Phase 2Completed

Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis

Start: Apr 2019Est. completion: May 201936 patients
Phase 2Completed
NCT02556801Allergy TherapeuticsSUBLIVAC FIX Phleum Prat.

Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy

Start: Sep 2015Est. completion: Oct 2016168 patients
Phase 2Completed

A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber

Start: Oct 2012Est. completion: Oct 2013188 patients
Phase 2Completed

SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding

Start: Jul 2012Est. completion: Apr 2013270 patients
Phase 2Completed

Efficacy Study in Allergic Rhinitis Patients After Intranasal Administration of AZD8848

Start: Sep 2010Est. completion: Jan 201293 patients
Phase 2Completed
NCT01103050SandozQAV680 + Cetirizine Placebo

A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine

Start: Mar 2010Est. completion: Jul 201060 patients
Phase 2Completed

The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis

Start: Jan 2010Est. completion: May 201064 patients
Phase 2Completed
NCT00973453Allergy TherapeuticsPURETHAL Mites 20,000 AUeq/ml

Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients

Start: Aug 2009Est. completion: Aug 201048 patients
Phase 2Completed
NCT00794144AlconOlopatadine Hydrochloride Nasal Spray 0.6%

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

Start: Oct 2008132 patients
Phase 2Completed

Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis

Start: Sep 2008Est. completion: Jan 200936 patients
Phase 2Completed

A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis

Start: Feb 2008Est. completion: May 200870 patients
Phase 2Completed

An Exploratory Study of the Effects of a Single Dose of QAX576 (an Interleukin-13 Monoclonal Antibody) on Simulated Hayfever

Start: Dec 200736 patients
Phase 2Completed

Two Formulations and Concentrations of Epinastine Nasal Spray Versus Azelastine Nasal Solution for Allergic Rhinitis

Start: Sep 2006Est. completion: Oct 2006131 patients
Phase 2Completed
NCT00152412UCB PharmaLevocetirizine oral solution

Open Study to Evaluate the Safety of Levocetirizine in Young Children (2 - 6 Years) Suffering From Allergic Rhinitis

Start: Jun 2004Est. completion: Dec 200430 patients
Phase 2Completed

Assess the Efficacy and Safety of Rhinocort Aqua

Start: Apr 2004Est. completion: May 2005650 patients
Phase 2Completed
NCT01989897Bryan Corporationsaline with 1mg/ml Histamine base

Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests

Start: Mar 2013Est. completion: Nov 20150
Phase 1/2Withdrawn

To Evaluate the Efficacy and Safety of TQC3564 Tablets in the Treatment of Persistent Allergic Rhinitis

Start: Sep 2022Est. completion: Dec 202312 patients
Phase 1Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

13 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 8,417 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.